{"name":"El Kendi Pharmaceuticals Manufacturing Company","slug":"el-kendi-pharmaceuticals-manufacturing-company","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Nimotuzumab ( h-R3)","genericName":"Nimotuzumab ( h-R3)","slug":"nimotuzumab-h-r3","indication":"Head and neck squamous cell carcinoma","status":"phase_3"}]}],"pipeline":[{"name":"Nimotuzumab ( h-R3)","genericName":"Nimotuzumab ( h-R3)","slug":"nimotuzumab-h-r3","phase":"phase_3","mechanism":"Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.","indications":["Head and neck squamous cell carcinoma","Non-small cell lung cancer","Colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQYkpfSm0wdGZyQS1BNTIzZU55QmlHdEEyQWZmNkRTOVZwRzdKNlI4S29ib1lMcEhEdVBndExsV2JpMkc2VTBLSHVzODhqWFZvS0h0R2t2bTJDWVJnQTdzOTFsUGgteFo2U1FKUTQ3VUNNaEUzWFZLYldaRDE1WkF2YWZwYUNIUjVsS0hpdDI3R1JoY055V050dnFDTDV6eTlSYURhYkRXWjJxVFBfb0lSc0Y4YjdfUnFCTzVLaFd2YS1rdHhLdzc0c0ZB?oc=5","date":"2026-01-27","type":"deal","source":"BioSpectrum Asia","summary":"MS Pharma Group signs exclusive biosimilars collaboration agreement with Hetero - BioSpectrum Asia","headline":"MS Pharma Group signs exclusive biosimilars collaboration agreement with Hetero","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOTHlXZVdVUmlCaDR5NHRVY3o1M05GTmJSN21hRVZIdHZTVk5ZTkVuYnhsTnZ1VVlRZUJSRkEyQTFvb0RySzRxQkN4d2JUVzE4V3NiaGhhTzN4R0sxcEZyeGtuUFktaHIyWWMxTlFvNVl3bmRRdGk0WGs0U19DVlVDRGxwZ1pBLVB4NFppb1NfNkl5d21HV20yRXpYcDdaRm4wR2tDWXppZUlqNld3eVdwSlpjS1FIcFZvQlkyTXFhVU14bmp3aDZzN2VOUUpFQQ?oc=5","date":"2026-01-26","type":"deal","source":"prnewswire.com","summary":"MS Pharma Group Signs Exclusive Biosimilars Partnership Agreement with Hetero - prnewswire.com","headline":"MS Pharma Group Signs Exclusive Biosimilars Partnership Agreement with Hetero","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPdG12LWpXUmo0QlNibHdIZjhpSzUwdF9oTkRWVlNCY0NSQ3V2R2p6MGstRjBnTTFMRE9VZE9UUF92bmZiZW9uYV8zQ05Fa1Zkd0toMGhTcG1uQTN2VDNOc2JjRGI3dnh3WTdmcWdtTVlrSXJhaXNkbGFBaTNRdWQ2cU1WcXdLSV9KQzZhN1p5d09pX29SbmVFWnNVQ0xJLTVTZ084VFlOczBsejVab0Vaek5hYmlzSXdmNlZIbUdB?oc=5","date":"2026-01-26","type":"deal","source":"Contract Pharma","summary":"MS Pharma Group, Hetero Group Partner to Localize Biosimilars in MENA Region - Contract Pharma","headline":"MS Pharma Group, Hetero Group Partner to Localize Biosimilars in MENA Region","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQR293ai04UFVIQWIyX0NucVk5bFRPUnJqSFlIUkFBcjZjWTVobGI3eG1mUTZjWjNpOXRkQUxpVVBfdlQ5eTBWQjYwWFdjWjhOZ0g0bXRBRF9KeXRTcEppNW9wNTlSR2w5TS1HLV9GNHF4Zlg0ZUctdlNOVXBnRXR6T3NkZlQ0a3Y5QlZOZ0RHOUM?oc=5","date":"2025-01-29","type":"pipeline","source":"Africa News Agency","summary":"Algeria : new plant dedicated to the fight against cancer - Africa News Agency","headline":"Algeria : new plant dedicated to the fight against cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQU3NUaEQxZk1PY1gzYU1iREZnOHlkWFRCUGIzZ1JTdWZRc0hKNG10QUpLUm5RNDFISzZ0ZEpnM3luUjdUSmxhWm13X1pLWUFFSGNzdUFoSjQ5SWx6ZHFUdXZrcENzM1lfSTQ4SG5ZMDFlNHNyeVBmSlgyRVFWNEpnX3NFOVQ3RkI5blIw?oc=5","date":"2021-11-09","type":"pipeline","source":"The New York Times","summary":"Johnson & Johnson’s Brand Falters Over Its Role in the Opioid Crisis (Published 2019) - The New York Times","headline":"Johnson & Johnson’s Brand Falters Over Its Role in the Opioid Crisis (Published 2019)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE9pLTl4N3VjaXdTWl9tU2d0WHpZRy1WVE0yX29TNDQ2M0lWNUVrOVZVbllXNjlEYTBLMVp3aUtoN3Z2TFp5VXl6ZDBZV0Ewd0FqN3ZaUGRGazRaVi1RRUlUQnk5NA?oc=5","date":"2020-08-02","type":"pipeline","source":"Pharmaceutical Executive","summary":"Country Report: Algeria - Pharmaceutical Executive","headline":"Country Report: Algeria","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}